09:55 AM EST - Aeterna Zentaris Inc. : announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.21 at $2.06.
